KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC
2012 ◽
Vol 35
(1)
◽
pp. 27-42
◽
2018 ◽
2007 ◽
Vol 17
(21)
◽
pp. 5863-5867
◽
2014 ◽
Vol 9
(9)
◽
pp. 1377-1384
◽
2019 ◽